The Insomnia Blog (Free subscription) | 22/08/2008
A new campaign called Sleeping Smart is about to happen as a joint project between the National Sleep Foundation and Sanofi-Aventis, a pharmaceutical company and the makers of the popular sleep aid Ambien. The goal is to educate people about...
The Temas Blog (Free subscription) | 20/08/2008
From Drugs for Neglected Diseases initiative (DNDi): Sanofi-aventis and DNDi welcome the Clinton Foundation announcement on ACTs and commit to providing fixed-dose combination “ASAQ” at equally low prices Sanofi-aventis and the non-profit Drugs for Neglected Diseases initiative (DNDi) welcome the agreement announced by Clinton Foundation HIV/AIDS Initiative (CHAI) to reduce the volatility and the price...
Medical News Today (Free subscription) | 14/08/2008
Sanofi-aventis and Bristol-Myers Squibb back today's decision by NICE (the National Institute for Health and Clinical Excellence) to review its guidance on vascular disease for clopidogrel (Plavix®) and dipyridamole. NICE originally planned to defer review of the guidance, called Technology Appraisal Number 90 (TAG90), until November 2010.
JJS Diabetes (Free subscription) | 14/08/2008
Sanofi-aventis announces the approval of APIDRA® (insulin glulisine [rDNA origin] injection), a rapid-acting insulin analog, by the European Commission for use in children 6 years of age and older. The recommendation was made based on results achieved in a phase III study comparing HUMALOG and APIDRA in Type 1 diabetic children and adolescents. Based on our experience to date, we believe APIDRA is...
Law Blog - WSJ.com (Free subscription) | 13/08/2008
Sanofi-Aventis has begun legal action against Canadian generic-drug maker Apotex, which is planning to sell a low-cost version of the cancer drug Taxotere in the U.S.
Red Orbit (Free subscription) | 12/08/2008
WALTHAM, Mass., Aug.
Red Orbit (Free subscription) | 12/08/2008
Sanofi-Aventis has announced that the FDA has assigned priority review status for its new drug application for Multaq.
Medical News Today (Free subscription) | 09/08/2008
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced that U.S. Food and Drug Administration (FDA) has assigned priority review status for its New Drug Application (NDA) for Multaq(R) (dronedarone). The priority review period begins on July 31, 2008.
Patent Baristas (Free subscription) | 08/08/2008
In a nonprecedential opinion, the U.S. Court of Appeals for the Federal Circuit gave the thumbs up to a district court decision that Plaintiff-Appellant Novo Nordisk A/S wasn’t getting a preliminary injunction out of Sanofi-Aventis after alleging that Sanofi’s SoloStar product infringed claims of Novo’s U.S. Patent No. 7,241,278. Novo Nordisk A/S v. Sanofi-Aventis (08-1225). In [...]
Fiercebiotech (Free subscription) | 08/08/2008
Sanofi-Aventis took a significant step forward in its effort to win an FDA approval for Multaq as a therapy for irregular heartbeat. The French company said that the FDA had agreed to give the drug--rejected by the FDA two years ago--a priority review. That should deliver a new verdict on the drug in six months. Multaq had earned a nonapprovable letter in 2006. The drug is intended to treat atrial...
Dr. Wes (Free subscription) | 08/08/2008
It seems Sanofi-Aventis's amiodarone analog drug, dronedarone (marketed as Multaq®), was granted a stay of execution by the FDA: Multaq appeared at one stage to have little future, after an early clinical trial showed excess mortality and the drug was rebuffed by regulators. As we recall : Dronedarone is structurally similar to amiodarone but lacking the iodine moiety — a feature of amiodarone that...
News & Information (Free subscription) | 08/08/2008
BRIDGEWATER, N.J., Aug. 8 /PRNewswire-FirstCall/ — Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that U.S. Food and Drug Administration (FDA) has assigned…Read more
Pharmalot (Free subscription) | 08/08/2008
Another shiny day here in the nation’s medicine chest. The weekend, though, is approaching quickly. So let us all hurry to complete those projects and dispense with those tiresome meetings. A break is in order. Meanwhile, here are a few items to help you along… Sanofi-Aventis Wins Fast-Track Review For Heart Med (Bloomberg News) Former Biopure Exec [...]
Market Watch (Free subscription) | 08/08/2008
LONDON (MarketWatch) -- Shares in Sanofi-Aventis climbed 4.1% after the company said the new drug application for its heart treatment Multaq has been granted priority review status by the U.S. Food & Drug Administration. Royal Bank of Scotland also upgraded the firm to buy from hold on Friday. "There are signs that management is starting to take a more realistic approach to R&D," the broker said....
Health - The Post Chronicle (Free subscription) | 08/08/2008
Women who take two commonly-used fertility treatments, including the Sanofi Aventis pill Clomid, do not have a significantly better chance of getting pregnant than those who try naturally,......
